Up a level |
Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Alicia Lazaro, Maria, Moots, Robert J ORCID: 0000-0001-7019-6211, Wollenhaupt, Juergen, Zerbini, Cristiano AF, Louw, Ingrid, Combe, Bernard et al (show 8 more authors)
(2016)
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
RHEUMATOLOGY, 55 (8).
pp. 1466-1476.
Durez, Patrick, Pavelka, Karel, Alicia Lazaro, Maria, Garcia-Kutzbach, Abraham, Moots, Robert J ORCID: 0000-0001-7019-6211, Amital, Howard, Govoni, Marinella and Vastesaeger, Nathan
(2018)
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.
CLINICAL RHEUMATOLOGY, 37 (5).
pp. 1417-1420.
Humby, Frances, Durez, Patrick, Buch, Maya H, Lewis, Myles J, Rizvi, Hasan, Rivellese, Felice, Nerviani, Alessandra, Giorli, Giovanni, Mahto, Arti, Montecucco, Carlomaurizio et al (show 20 more authors)
(2021)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
LANCET, 397 (10271).
pp. 305-317.